HIF1A and sarcoma: This conflicts with other preclinical studies showing inhibition of metastases with VEGF inhibitors33 as well as clinical studies demonstrating that bevacizumab as single-agent therapies can prolong patient survival against metastatic renal cell cancer and other cancers.34, 35 The effects of VEGF inhibition in primary sarcomas on hypoxia, HIF-1α activity and HIF-related phenotypes such as tumor progression, metastasis and radiation response are currently unknown.